Administration and Data Analytic Core

HARP ADA项目总结 基于20年来在NIAAA资助的艾滋病毒和酒精问题大型协调研究项目方面的经验， 退伍军人老龄化队列研究（VACS）和我们的大家庭，良好的特点，国家 退伍军人医疗保健管理局（VA）队列（VACo家族）为研究提供了前所未有的资源 在有和没有艾滋病病毒感染的老年人中，酒精的含量。电子健康记录（EHR） 经过严格的数据清理和表型验证，VACo家族共享共同的数据 元素，包括20年的酒精和健康结果的纵向数据;它还包括行为 相似的未感染个体，使我们能够描述HIV感染在确定酒精中的作用 相关成果;并支持有针对性的转化和干预研究。为了支持卓越的 问题解决，研究设计和分析，我们已经培养了一个国际合作网络， 专家这一完善的基础设施带来了卓越的生产力。我们的调查人员 使用来自VACo家族的数据产生了超过500篇同行评审的出版物，引用次数超过26，000次（h指数79）。 我们已经成功地协调了观察和干预研究，重点是酒精的作用， 确定艾滋病毒感染者和非艾滋病毒感染者的可改变结果。我们也感到自豪， 教育，培训，职业发展和领导经验，我们提供年轻的调查员，许多 他们已经过渡到独立的NIH和VA资助。我们持续的使命是建立和传播 优化对因酒精而受到医疗伤害的艾滋病毒（PAH）感染者的护理所需的证据 通过良好协调和充分整合的观察和干预研究。获得国家 EHR数据，包括药物填充/再填充数据，我们处于独特的位置，可以研究与 同时使用酒精和多种药物（多种药物）。为了完成我们更大的使命， 计划项目申请支持创建艾滋病毒和酒精研究中心，重点是 多重用药（HARP），以解决与有害的酒精使用和多重用药（AP风险）相关的风险。的 ADA核心，分为行政和数据分析部分，由经验丰富的研究组成， 协调员和数据管理、高性能计算 生物统计学和人工智能核心将解决清洁和分析大型 规模，纵向EHR数据与其他数据源（例如，调查，生物标志物和遗传学）， 支持观察性和试点干预研究。通过促进和通报数据访问、分析方法， 并与我们更大的网络保持良好的通信线路，ADA核心将增强 HARP的重要性和影响，提供了资助项目无法获得的经验和资源 分开凭借我们的经验、资源和动力，ADA核心具有独特的优势，可以解决 PAH中的AP风险。

HARP ADA PROJECT SUMMARY Built on two decades of experience with large coordinated NIAAA-funded research projects on HIV and alcohol, The Veterans Aging Cohort Study (VACS) and our extended family of large, well characterized, national Veterans Healthcare Administration (VA) Cohorts (VACo Family) offer an unprecedented resource for the study of alcohol among people aging with and without HIV infection. Derived from Electronic Health Record (EHR), and subjected to rigorous data cleaning and phenotype validation, the VACo Family shares common data elements, including 20 years of longitudinal data on alcohol and health outcomes; it also includes behaviorally similar uninfected individuals, allowing us to characterize the role of HIV infection in determining alcohol associated outcomes; and supports targeted translational and intervention studies. To support excellence in the questions addressed, study design and analyses, we have cultivated an international collaborative network of experts. This well-established infrastructure has resulted in exceptional productivity. Our investigators have used data from the VACo Family to produce >500 peer reviewed publications, cited >26,000 times (h-index 79). We have successfully coordinated observational and intervention studies focused on the role of alcohol in determining modifiable outcomes among people aging with and without HIV infection. We are also proud of the education, training, career development, and leadership experience we offer young investigators, many of whom have transitioned to independent NIH and VA funding. Our ongoing mission is to build and disseminate the evidence needed to optimize care for people aging with HIV (PAH) experiencing medical harm from alcohol through well-coordinated and fully integrated observational and intervention studies. With access to national EHR data including medication fill/refill data, we are uniquely positioned to study harms associated with concurrent use of alcohol and multiple medications (polypharmacy). In service to our larger mission, our Program Project application supports the creation of the HIV and Alcohol Research center focused on Polypharmacy (HARP) to address risks associated with harmful alcohol use and polypharmacy (AP risk). The ADA Core, organized into administrative and data analytic sections, is composed of seasoned study coordinators and an expanded group of experts in data management, high performance computing, biostatistics, and artificial intelligence. The Core will address the challenges of cleaning and analyzing large scale, longitudinal EHR data combined with other data sources (e.g., surveys, biomarkers, and genetics) to support observational and pilot intervention studies. By facilitating and informing data access, analytic approach, and maintaining excellent lines of communication with our larger network, the ADA Core will enhance the significance and impact of HARP, providing experience and resources not available were projects funded separately. With our experience, resources, and momentum, the ADA Core is uniquely positioned to address AP risk among PAH.